4-[(5-bromopyridin-2-yl)oxy]benzaldehyde | 866114-77-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(5-bromopyridin-2-yl)oxy]benzaldehyde
• 英文别名: 4-(5-bromo-pyridin-2-yloxy)-benzaldehyde；4-(5-bromopyridin-2-yl)oxybenzaldehyde
• CAS: 866114-77-4
• 化学式: C₁₂H₈BrNO₂
• 分子量: 278.105
• InChiKey: ZLYYKYLUUDIFNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(5-bromopyridin-2-yl)oxy]benzaldehyde 在 甲醇 、 sodium tetrahydroborate 作用下， 以89 %的产率得到(4-((5-bromopyridin-2-yl)oxy)phenyl)methanol
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1
• 作为产物：
  描述：

  2,5-二溴吡啶 、 对羟基苯甲醛 在 potassium carbonate 作用下， 以 异丁酰胺 为溶剂， 反应 8.0h， 以36%的产率得到4-[(5-bromopyridin-2-yl)oxy]benzaldehyde
  参考文献：
  名称：

  [EN] OPIOID RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RECEPTEURS OPIOIDES

  摘要：

  公式（I）的化合物，其中变量X1、X2、B、D、R1至R7（包括R3'、p、y、q和z）的定义，或者其药用盐、溶剂化合物、对映体、外消旋体、二对映异构体或其混合物，用于治疗、预防或改善肥胖和相关疾病。

  公开号：

  WO2005092836A1

文献信息

• OPIOID RECEPTOR ANTAGONISTS
  申请人：Chappell Donald Mark

  公开号：US20070066658A1

  公开（公告）日：2007-03-22

  A compound of the formula (I) wherein the variables X 1 , X 2 , B, D, R 1 to R 7 including R 3′ , p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  本发明公开了一种式(I)的化合物，其中变量X1、X2、B、D、R1到R7包括R3'、p、y、q和z如定义所述，或其药学上可接受的盐、溶剂化物、对映体、外消旋体、对映异构体或其混合物，用于治疗、预防或缓解肥胖和相关疾病。
• Diphenylether amide derivatives as opioid receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US07378448B2

  公开（公告）日：2008-05-27

  A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed

  公开了一种化合物的式子（I），其中变量X1，X2，B，D，R1到R7包括R3′，p，y，q和z，如定义或药学上可接受的盐，溶剂化合物，对映体，外消旋体，二对映异构体或其混合物，用于治疗，预防或改善肥胖症及相关疾病。
• Opioid receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US07902372B2

  公开（公告）日：2011-03-08

  A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  公式（I）的化合物被揭示，其中变量X1、X2、B、D、R1到R7包括R3'、p、y、q和z，如定义或药学上可接受的盐、溶剂合物、对映体、消旋体、非对映异构体或其混合物，可用于治疗、预防或改善肥胖症和相关疾病。
• Opioid Receptor Antagonists
  申请人：Chappell Mark Donald

  公开号：US20110105571A1

  公开（公告）日：2011-05-05

  A compound of the formula (I) wherein the variables X 1 , X 2 , B, D, R 1 to R 7 including R 3′ , p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  本发明揭示了具有式（I）的化合物，其中变量X1、X2、B、D、R1到R7包括R3'、p、y、q和z如定义或其药学上可接受的盐、溶剂化物、对映体、外消旋体、非对映体异构体或其混合物，用于治疗、预防或改善肥胖症及相关疾病。
• Partially saturated nitrogen-containing heterocyclic compound
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：US09422240B2

  公开（公告）日：2016-08-23

  There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I′): (in the above-mentioned general formula (I′), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

  提供了具有优越的PHD2抑制效果的化合物，其通式表示为(I'):(在上述通式(I')中，W、Y、R2、R3、R4和Y4如上所述)，或其药学上可接受的盐。